文摘
摘要目的:确定的效用τ宠物配体18f - av - 1451额颞叶痴呆(FTD)谱系障碍。
背景:异常聚合τ蛋白是一个潜在的FTD谱系障碍的病理特征。准确识别将临床试验的关键。
设计/方法:我们评估行为变异额颞叶痴呆(bvFTD, n = 5),迟滞型变体原发性进行性失语(nfvPPA, n = 9),语义变体原发性进行性失语(svPPA, n = 2),进步supranculear麻痹(PSP, n = 10), corticobasal综合症(CBS, n = 9),C9ORF72突变(n = 3),MAPT突变携带者(n = 5)和amyloid-negative正常对照组(NC, n = 22)18f - av - 1451的宠物。18F av - 1451图像总结,和标准摄入值比率计算t = 80 - 100分钟的使用意味着活动小脑灰质区域(不含齿状核)作为参考。
结果:数控显示不同程度的吸收在内侧颞叶皮层中脑、基底神经节和小脑。有症状的MAPT运营商(CDR 1 - 2)增加额颞叶18f - av - 1451吸收比轻度或无症状携带者(CDR 0 - 0.5)。在两个bvFTD情况下,吸收的额颞叶和顶叶区域。在PSP和nfvPPA voxel-wise相比数控显示增加吸收双边在苍白球(p (FWE) < 0.05)、壳核、丘脑、丘脑核背侧中脑、小脑齿状核(p < 0.001未修正的)PSP和双边额盖,在nfvPPA额中回(p < 0.001未调整的)。CBS主题显示不同程度的核吸收,苍白球和白质。吸收偏侧性匹配一侧nfvPPA和哥伦比亚广播公司(CBS)症状。吸收是双边侧,颞极svPPA情况下,额极C9ORF72用例。
结论:总之,高18f - av - 1451吸收匹配的预期分布τFTD谱系障碍的病理。然而,高架保留在NC和神经退行性地区的皮质下区域预测TDP-43患者病理质疑特异性的绑定。的18f - av - 1451示踪剂在FTD谱系障碍需要进一步探索。
研究支持:
Avid Radiopharmaceuticals启用[18 f] av - 1451的使用示踪剂,但没有提供直接资助这个研究是τ财团的支持
披露:蔡博士没有披露。Bejanin博士没有披露。Schonhaut博士没有披露。Ossenkoppele博士没有披露。奥尼尔博士没有披露。Janabi博士没有披露。贝克博士没有披露。Lazaris博士没有披露。Ayakta博士没有披露。Tammewar博士没有披露。 Dr. Tempini has received personal compensation in an editorial capacity from Neuroimage Clinical. Dr. Miller has nothing to disclose. Dr. Boxer has received personal compensation for activities with Abbvie, Asceneuron, Janssen, Merck for consulting. Dr. Jagust has received personal compensation for activities with Genentech Inc., Synarc, Janssen Alzheimer Immunotherapy, TauRx, and Siemens as a consultant. Dr. Rabinovici has received personal compensation for activities with Eisai, Roche, Lundbeck, and Putnam as a speaker or consultant. Dr. Rabinovici has received research support from NIH, Alzheimer's Association, Tau Consortium, American College of Radiology, Michael J Fox Foundation, Association for Frontotemporal Degneration, Avid Radiopharmaceuticals/Eli Lilly, GE Healthcare, and Piramal Imaging.
